Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD1 | P11586 | 3/20 | 0.68 |
| ▸ | DHFR | P00374 | 2/20 | 0.65 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.59 |
| ▸ | FPGS | Q05932 | 2/20 | 0.52 |
| ▸ | MTHFD2 | P13995 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ATIC | P31939 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TYMS | P04818 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomefolic Acid SCHEMBL16466806 | 1.00 | MTHFD1 (0.68) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| Levomefolic Acid SCHEMBL20440869 | 1.00 | MTHFD1 (0.68) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| Levomefolic Acid SCHEMBL79586 | 1.00 | MTHFD1 (0.68) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| Levomefolic Acid SCHEMBL7953180 | 1.00 | MTHFD1 (0.68) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| Levomefolic Acid SCHEMBL3442396 | 0.99 | MTHFD1 (0.67) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| SCHEMBL26045337 | 0.94 | MTHFD1 (0.60) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| SCHEMBL25849429 | 0.94 | MTHFD1 (0.60) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| SCHEMBL17931045 | 0.93 | MTHFD1 (0.59) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| Ketotrexate SCHEMBL1228871 | 0.92 | MTHFD1 (0.80) | MTHFD1DHFRSOSTFPGSMTHFD2 | |
| SCHEMBL26045357 | 0.90 | MTHFD1 (0.59) | MTHFD1DHFRSOSTFPGSMTHFD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025017570-A1 | SYNERGISTIC BIOACTIVE COMPOSITION FOR MODULATING CHOLINE DEHYDROGENASE (CHD) ACTIVITY | Celagenex Research (India) Pvt. Ltd. (IN) | 2025-01-23 | — | — | WO | disclosed |
| US-20230272442-A1 | 5-METHYLFOLATE PRODUCING MICROORGANISM | CHIFENG PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230272442-A1 | 5-METHYLFOLATE PRODUCING MICROORGANISM | CHIFENG PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230087806-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2023-03-23 | — | — | US | disclosed |
| EP-3940071-A1 | 5-METHYLFOLATE PRODUCING MICROORGANISM | Chifeng Pharmaceutical Co., Ltd (CN) | 2022-01-19 | — | — | EP | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20200033361-A1 | Detection and Quantitation Method for Proteomics of Post-Translational Modifications | SICHUAN UNIVERSITY (CN) | 2020-01-30 | — | — | US | disclosed |
| CN-108627647-A | A kind of detection of posttranslational modification proteomics and quantitative approach | 四川大学 | 2018-10-09 | — | — | CN | disclosed |
| US-20170049777-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2017-02-23 | — | — | US | disclosed |
| WO-2016185412-A1 | IMMEDIATE RELEASE FORMULATIONS | NESTEC S.A. (CH) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016185413-A1 | MODIFIED RELEASE FORMULATIONS | NESTEC S.A. (CH) | 2016-11-24 | — | — | WO | disclosed |
| US-20160287624-A1 | Water-Soluble Vitamins to Increase Oral Absorption and Bioavailability | NESTEC SA (CH) | 2016-10-06 | — | — | US | disclosed |
| US-20160271155-A1 | Vitamin Formulations | NESTEC SA (CH) | 2016-09-22 | — | — | US | disclosed |
| WO-2015077509-A1 | VITAMIN FORMULATIONS | NESTEC S.A. (CH) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077511-A1 | FORMULATION FOR WATER-SOLUBLE VITAMINS TO INCREASE ORAL ABSORPTION AND BIOAVAILABILITY | NESTEC S.A. (CH) | 2015-05-28 | — | — | WO | disclosed |
| US-20150050261-A1 | DIETARY AND NUTRITIONAL SUPPLEMENTS CONTAINING AN OMEGA-3 FATTY ACID OF PLANT-BASED ORIGIN AND A FOLATE DERIVATIVE | CIT BANK, N.A., AS COLLATERAL AGENT | 2015-02-19 | — | — | US | disclosed |
| US-20150050261-A1 | DIETARY AND NUTRITIONAL SUPPLEMENTS CONTAINING AN OMEGA-3 FATTY ACID OF PLANT-BASED ORIGIN AND A FOLATE DERIVATIVE | CIT BANK, N.A., AS COLLATERAL AGENT | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230087806-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | MTHFD1 302/4885DHFR 591/4885SOST 4546/4885 |
| US-20150050261-A1 | DIETARY AND NUTRITIONAL SUPPLEMENTS CONTAINING AN OMEGA-3 FATTY ACID OF PLANT-BASED ORIGIN AND A FOLATE DERIVATIVE | FABP3, FABP2, ELOVL3 | MTHFD1 59/4885DHFR 38/4885SOST 846/4885 |
| US-20160271155-A1 | Vitamin Formulations | CYP24A1, VDR, CYP2R1 | MTHFD1 683/4885DHFR 381/4885SOST 409/4885 |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | MTHFD1 302/4885DHFR 591/4885SOST 4546/4885 |
| US-20160287624-A1 | Water-Soluble Vitamins to Increase Oral Absorption and Bioavailability | CYP24A1, CYP2R1, VDR | MTHFD1 721/4885DHFR 347/4885SOST 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.